{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:29:04Z","timestamp":1793816944862,"version":"4.6.1"},"reference-count":435,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020951","name":"Fonds de recherche du Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020951","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.pharmr.2026.100128","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:11:07Z","timestamp":1772151067000},"page":"100128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting of kinases to treat neurodegenerative diseases"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9863-0800","authenticated-orcid":false,"given":"Tara","family":"Shomali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-3371","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Trempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmr.2026.100128_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.864339","article-title":"The global burden of motor neuron disease: an analysis of the 2019 global burden of disease study","volume":"13","author":"Park","year":"2022","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib3","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer\u2019s disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00002093-200110000-00002","article-title":"Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050","volume":"15","author":"Hebert","year":"2001","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases\u2014the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrd2111","article-title":"Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases","volume":"6","author":"Mazanetz","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease","volume":"44","author":"Pais\u00e1n-Ru\u00edz","year":"2004","journal-title":"Neuron"},{"issue":"5674","key":"10.1016\/j.pharmr.2026.100128_bib8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.1096284","article-title":"Hereditary early-onset Parkinson\u2019s disease caused by mutations in PINK1","volume":"304","author":"Valente","year":"2004","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0047-6374(01)00342-6","article-title":"Differential activation of neuronal ERK, JNK\/SAPK and p38 in Alzheimer disease: the \u201ctwo hit\u201d hypothesis","volume":"123","author":"Zhu","year":"2001","journal-title":"Mech Ageing Dev"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jocn.2013.08.017","article-title":"Peripheral expression of MAPK pathways in Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"21","author":"Wang","year":"2014","journal-title":"J Clin Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/JAD-2001-3107","article-title":"Localization of active forms of c-Jun kinase (JNK) and p38 kinase in Alzheimer\u2019s disease brains at different stages of neurofibrillary degeneration","volume":"3","author":"Pei","year":"2001","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrd1132","article-title":"Targeting JNK for therapeutic benefit: from junk to gold?","volume":"2","author":"Manning","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100128_bib13","doi-asserted-by":"crossref","first-page":"10433","DOI":"10.1073\/pnas.181182298","article-title":"Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson\u2019s disease","volume":"98","author":"Xia","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib14","first-page":"265","article-title":"JNK signaling pathway activity alterations in the rat hippocampus: effect of age, Alzheimer\u2019s disease-like pathology development, and the JNK inhibitor IQ-1S","volume":"90","author":"Muraleva","year":"2025","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmr.2026.100128_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103970","article-title":"Human tau accumulation promotes glycogen synthase kinase-3\u03b2 acetylation and thus upregulates the kinase: a vicious cycle in Alzheimer neurodegeneration","volume":"78","author":"Zhou","year":"2022","journal-title":"EBiomedicine"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2990.2006.00795.x","article-title":"Increased level of active GSK-3\u03b2 in Alzheimer\u2019s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration","volume":"33","author":"Leroy","year":"2007","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.nbd.2004.06.007","article-title":"Activation of the neuronal c-Abl tyrosine kinase by amyloid-\u03b2-peptide and reactive oxygen species","volume":"17","author":"Alvarez","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3233\/JAD-2009-1062","article-title":"Altered subcellular distribution of c-Abl in Alzheimer\u2019s disease","volume":"17","author":"Jing","year":"2009","journal-title":"J Alzheimers Dis"},{"issue":"38","key":"10.1016\/j.pharmr.2026.100128_bib19","doi-asserted-by":"crossref","first-page":"16691","DOI":"10.1073\/pnas.1006083107","article-title":"Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin\u2019s ubiquitination and protective function","volume":"107","author":"Ko","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib20","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1172\/JCI85456","article-title":"Activation of tyrosine kinase c-Abl contributes to \u03b1-synuclein-induced neurodegeneration","volume":"126","author":"Brahmachari","year":"2016","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib23","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"issue":"25","key":"10.1016\/j.pharmr.2026.100128_bib24","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-controlled trial of an Oral BTK Inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ana.10113","article-title":"A new locus for Parkinson\u2019s disease (PARK8) maps to chromosome 12p11.2-q13.1","volume":"51","author":"Funayama","year":"2002","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"issue":"46","key":"10.1016\/j.pharmr.2026.100128_bib27","doi-asserted-by":"crossref","first-page":"16842","DOI":"10.1073\/pnas.0507360102","article-title":"Parkinson\u2019s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity","volume":"102","author":"West","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100128_bib28","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.15252\/embr.201540514","article-title":"(Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation","volume":"16","author":"Fiesel","year":"2015","journal-title":"EMBO Rep"},{"key":"10.1016\/j.pharmr.2026.100128_bib29","article-title":"Pharmacological PINK1 activation ameliorates Pathology in Parkinson\u2019s disease models","volume":"2023","author":"Chin","year":"2023","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib30","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.bbrc.2009.10.107","article-title":"CaMKII uses GTP as a phosphate donor for both substrate and autophosphorylation","volume":"390","author":"Bostrom","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib31","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/0006-2952(82)90028-4","article-title":"Selective inhibition of a cyclic nucleotide independent protein kinase (G type casein kinase) by quercetin and related polyphenols","volume":"31","author":"Cochet","year":"1982","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib32","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1006\/bbrc.1995.1087","article-title":"Protein kinase C delta accepts GTP for autophosphorylation","volume":"206","author":"Gschwendt","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"issue":"5600","key":"10.1016\/j.pharmr.2026.100128_bib33","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib34","first-page":"3034","article-title":"Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors","volume":"8","author":"Dagher","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib35","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/cells13010047","article-title":"Targeted inhibitors of EGFR: structure, biology, biomarkers, and clinical applications","volume":"13","author":"Shaban","year":"2023","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100128_bib37","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/nsmb859","article-title":"Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition","volume":"11","author":"Ohren","year":"2004","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nsb770","article-title":"Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site","volume":"9","author":"Pargellis","year":"2002","journal-title":"Nat Struct Biol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib39","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cgatekeeper door\u201d: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2026.100128_bib40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.pharmr.2026.100128_bib41","article-title":"Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models","author":"Hertz","year":"2024","journal-title":"Res Sq"},{"key":"10.1016\/j.pharmr.2026.100128_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib43","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41591-025-03564-3","article-title":"Women twice as likely to develop Alzheimer\u2019s disease as men\u2014but scientists do not know why","volume":"31","author":"Moutinho","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12017-009-8104-z","article-title":"An overview of APP processing enzymes and products","volume":"12","author":"Chow","year":"2010","journal-title":"NeuroMolecular Med"},{"issue":"5580","key":"10.1016\/j.pharmr.2026.100128_bib45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"issue":"5082","key":"10.1016\/j.pharmr.2026.100128_bib46","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1126\/science.1411576","article-title":"Genetic linkage evidence for a familial Alzheimer\u2019s disease locus on chromosome 14","volume":"258","author":"Schellenberg","year":"1992","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib48","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","article-title":"A protein factor essential for microtubule assembly","volume":"72","author":"Weingarten","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7618","key":"10.1016\/j.pharmr.2026.100128_bib49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib50","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1007\/s12035-022-03164-z","article-title":"Role of tau in various tauopathies, treatment approaches, and emerging role of nanotechnology in neurodegenerative disorders","volume":"60","author":"Kaur","year":"2023","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.pharmr.2026.100128_bib51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fneur.2013.00083","article-title":"The importance of tau phosphorylation for neurodegenerative diseases","volume":"4","author":"Noble","year":"2013","journal-title":"Front Neurol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib52","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1007\/s12035-020-02034-w","article-title":"Hyperphosphorylation renders tau prone to aggregate and to cause cell death","volume":"57","author":"Liu","year":"2020","journal-title":"Mol Neurobiol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib53","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","article-title":"Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010\u20132015","volume":"26","author":"Mehta","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2515\/therapie\/2010054","article-title":"[Molecular actors in Alzheimer\u2019s disease: which diagnostic and therapeutic consequences?]","volume":"65","author":"Bu\u00e9e","year":"2010","journal-title":"Therapie"},{"issue":"8000","key":"10.1016\/j.pharmr.2026.100128_bib55","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer\u2019s disease","volume":"2","author":"Davies","year":"1976","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib56","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1471-4159.1981.tb04484.x","article-title":"Aging decreases oxidative metabolism and the release and synthesis of acetylcholine","volume":"37","author":"Gibson","year":"1981","journal-title":"J Neurochem"},{"issue":"6069","key":"10.1016\/j.pharmr.2026.100128_bib57","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/321519a0","article-title":"NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones","volume":"321","author":"MacDermott","year":"1986","journal-title":"Nature"},{"issue":"A","key":"10.1016\/j.pharmr.2026.100128_bib58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2013.08.013","article-title":"Dysfunctional synapse in Alzheimer\u2019s disease\u2014A focus on NMDA receptors","volume":"76","author":"Mota","year":"2014","journal-title":"Neuropharmacology"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2026.100128_bib59","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/gps.938","article-title":"The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer\u2019s disease: preclinical evidence","volume":"18","author":"Danysz","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib60","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1002\/alz.13755","article-title":"Results from the long-term extension of PRIME: a randomized Phase 1b trial of aducanumab","volume":"20","author":"Chen","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib61","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1021\/ml2001455","article-title":"The discovery of VX-745: a novel and selective p38\u03b1 kinase inhibitor","volume":"2","author":"Duffy","year":"2011","journal-title":"ACS Med Chem Lett"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib62","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1021\/acs.jmedchem.9b00058","article-title":"A selective and brain penetrant p38\u03b1MAPK inhibitor candidate for neurologic and neuropsychiatric disorders that attenuates neuroinflammation and cognitive dysfunction","volume":"62","author":"Roy","year":"2019","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib63","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/gtc.12022","article-title":"Activity-based kinase profiling of approved tyrosine kinase inhibitors","volume":"18","author":"Kitagawa","year":"2013","journal-title":"Genes Cells"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib64","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1074\/jbc.M111.306472","article-title":"Evidence for irreversible inhibition of glycogen synthase kinase-3\u03b2 by tideglusib","volume":"287","author":"Dom\u00ednguez","year":"2012","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100128_bib65","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/brain\/122.12.2279","article-title":"A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases","volume":"122","author":"Lucchinetti","year":"1999","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib66","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib67","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/jpm11101006","article-title":"What can we learn from sex differences in MS?","volume":"11","author":"Coyle","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.pharmr.2026.100128_bib68","first-page":"555","article-title":"Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis","volume":"8","author":"di Nuzzo","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib69","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037297","article-title":"Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment","volume":"103","author":"Haki","year":"2024","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib70","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ana.410330203","article-title":"Multiple sclerosis: remyelination of nascent lesions","volume":"33","author":"Prineas","year":"1993","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib71","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/ard-2024-225587","article-title":"Defects in B-lymphopoiesis and B-cell maturation underlie prolonged B-cell depletion in ANCA-associated vasculitis","volume":"83","author":"Thiel","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib72","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1172\/JCI68775","article-title":"Specific peripheral B cell tolerance defects in patients with multiple sclerosis","volume":"123","author":"Kinnunen","year":"2013","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib73","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.4049\/jimmunol.1200658","article-title":"CD8 T cell-initiated blood-brain barrier disruption is independent of neutrophil support","volume":"189","author":"Johnson","year":"2012","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib74","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11481-019-09839-0","article-title":"Inhibition of bruton's tyrosine kinase modulates microglial phagocytosis: therapeutic implications for Alzheimer\u2019s disease","volume":"14","author":"Keaney","year":"2019","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6578","key":"10.1016\/j.pharmr.2026.100128_bib75","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib76","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","article-title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials","volume":"23","author":"Montalban","year":"2024","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib77","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40268-024-00468-4","article-title":"Comparative CNS pharmacology of the bruton's tyrosine kinase (BTK) inhibitor Tolebrutinib versus Other BTK inhibitor candidates for treating multiple sclerosis","volume":"24","author":"Turner","year":"2024","journal-title":"Drugs R D"},{"key":"10.1016\/j.pharmr.2026.100128_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177747","article-title":"Next generation bruton's tyrosine kinase inhibitors\u2014characterization of in vitro potency and selectivity","volume":"1002","author":"Pulz","year":"2025","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib79","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1021\/acs.jmedchem.0c00597","article-title":"A fast and clean BTK inhibitor","volume":"63","author":"Gabizon","year":"2020","journal-title":"J Med Chem"},{"issue":"16_Supplement","key":"10.1016\/j.pharmr.2026.100128_bib80","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-CT132","article-title":"Abstract CT132: orelabrutinib, a potent and selective Bruton's tyrosine kinase inhibitor with superior safety profile and excellent PK\/PD properties","volume":"80","author":"Zhang","year":"2020","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1295","article-title":"Next-generation bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells","volume":"10","author":"Bame","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.pharmr.2026.100128_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib83","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.parkreldis.2015.05.002","article-title":"LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis","volume":"21","author":"Gan-Or","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100128_bib84","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/dtb.12.21.83","article-title":"Sinemet","volume":"12","year":"1974","journal-title":"Drug Ther Bull"},{"issue":"suppl 2","key":"10.1016\/j.pharmr.2026.100128_bib85","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1007\/s00415-010-5728-8","article-title":"Pharmacokinetics of levodopa","volume":"257","author":"Contin","year":"2010","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib86","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/aian.AIAN_239_17","article-title":"Levodopa-induced dyskinesia: clinical features, pathophysiology, and medical management","volume":"20","author":"Pandey","year":"2017","journal-title":"Ann Indian Acad Neurol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib87","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s00415-017-8523-y","article-title":"Efficacy of rasagiline and selegiline in Parkinson\u2019s disease: a head-to-head 3-year retrospective case-control study","volume":"264","author":"Cereda","year":"2017","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib88","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2013.096776","article-title":"Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors","volume":"99","author":"Kim","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib89","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1021\/jm401654j","article-title":"Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors","volume":"57","author":"Estrada","year":"2014","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib90","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1073\/pnas.97.2.571","article-title":"Acceleration of oligomerization, not fibrillization, is a shared property of both \u03b1-synuclein mutations linked to early-onset Parkinson\u2019s disease: implications for pathogenesis and therapy","volume":"97","author":"Conway","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2026.100128_bib91","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00592","article-title":"Native \u03b1-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2\/VAMP2","volume":"2","author":"Diao","year":"2013","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib92","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","article-title":"Mice lacking \u03b1-synuclein display functional deficits in the nigrostriatal dopamine system","volume":"25","author":"Abeliovich","year":"2000","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib93","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00702-019-02025-9","article-title":"\u0391-synuclein in Parkinson\u2019s disease: causal or bystander?","volume":"126","author":"Riederer","year":"2019","journal-title":"J Neural Transm"},{"issue":"5646","key":"10.1016\/j.pharmr.2026.100128_bib94","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"\u0391-synuclein locus triplication causes Parkinson\u2019s disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib95","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ana.21541","article-title":"A critical evaluation of the Braak staging scheme for Parkinson\u2019s disease","volume":"64","author":"Burke","year":"2008","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib96","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/cells10030598","article-title":"The nigral coup in Parkinson\u2019s disease by \u03b1-synuclein and its associated rebels","volume":"10","author":"Sian-Hulsmann","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib97","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"\u0391-synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat Cell Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib98","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1074\/jbc.C800206200","article-title":"Polo-like kinase 2 (PLK2) phosphorylates \u03b1-synuclein at serine 129 in central nervous system","volume":"284","author":"Inglis","year":"2009","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100128_bib99","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202357145","article-title":"Dynamic reversibility of \u03b1-synuclein serine-129 phosphorylation is impaired in synucleinopathy models","volume":"24","author":"Ramalingam","year":"2023","journal-title":"EMBO Rep"},{"issue":"41","key":"10.1016\/j.pharmr.2026.100128_bib100","doi-asserted-by":"crossref","first-page":"E3945","DOI":"10.1073\/pnas.1309991110","article-title":"Polo-like kinase 2 regulates selective autophagic \u03b1-synuclein clearance and suppresses its toxicity in vivo","volume":"110","author":"Oueslati","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib101","first-page":"273","article-title":"Neflamapimod: clinical phase 2b-ready oral small molecule inhibitor of p38\u03b1 to reverse synaptic dysfunction in early Alzheimer\u2019s disease","volume":"4","author":"Alam","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066226","article-title":"Development of novel in vivo chemical probes to address CNS protein kinase involvement in synaptic dysfunction","volume":"8","author":"Watterson","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib103","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100128_bib104","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol"},{"issue":"4\u20135","key":"10.1016\/j.pharmr.2026.100128_bib105","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/13524585241234783","article-title":"Efficacy and safety results after >3.5 years of treatment with the bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study","volume":"30","author":"Montalban","year":"2024","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib106","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1474-4422(25)00174-7","article-title":"Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study","volume":"24","author":"Bar-Or","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmr.2026.100128_bib107","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/637059","article-title":"Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation","volume":"2014","author":"Reinwald","year":"2014","journal-title":"BioMed Res Int"},{"issue":"679","key":"10.1016\/j.pharmr.2026.100128_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abp9352","article-title":"The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson\u2019s disease","volume":"15","author":"Karuppagounder","year":"2023","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejps.2005.02.001","article-title":"Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat","volume":"25","author":"Vita","year":"2005","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib110","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1021\/acschembio.6b00306","article-title":"Inhibitors of glycogen synthase kinase 3 with exquisite kinome-wide selectivity and their functional effects","volume":"11","author":"Wagner","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib111","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1021\/acs.jmedchem.3c00133","article-title":"evaluation of potent and brain-penetrant imidazo[1,2-b]pyridazines as glycogen synthase Kinase-3\u03b2 (GSK-3\u03b2) inhibitors","volume":"66","author":"Hartz","year":"2023","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib112","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.1021\/acs.jmedchem.3c00364","article-title":"Discovery of 2-(anilino)pyrimidine-4-carboxamides as highly potent, selective, and orally active glycogen synthase Kinase-3 (GSK-3) inhibitors","volume":"66","author":"Hartz","year":"2023","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib113","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1021\/cn1001107","article-title":"JNK inhibition protects dopamine neurons and provides behavioral improvement in a rat 6-hydroxydopamine model of Parkinson\u2019s disease","volume":"2","author":"Crocker","year":"2011","journal-title":"ACS Chem Neurosci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib114","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","article-title":"Discovery of a 3-(4-pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity","volume":"60","author":"Scott","year":"2017","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib115","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.29297","article-title":"LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson\u2019s disease","volume":"38","author":"Jennings","year":"2023","journal-title":"Mov Disord"},{"issue":"648","key":"10.1016\/j.pharmr.2026.100128_bib116","doi-asserted-by":"crossref","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","article-title":"Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease","volume":"14","author":"Jennings","year":"2022","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib117","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","article-title":"Diversity and versatility of p38 kinase signalling in health and disease","volume":"22","author":"Canovas","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib118","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0092-8674(94)90278-X","article-title":"Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27","volume":"78","author":"Freshney","year":"1994","journal-title":"Cell"},{"issue":"5173","key":"10.1016\/j.pharmr.2026.100128_bib119","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.7914033","article-title":"A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells","volume":"265","author":"Han","year":"1994","journal-title":"Science"},{"issue":"6508","key":"10.1016\/j.pharmr.2026.100128_bib120","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/372739a0","article-title":"A protein kinase involved in the regulation of inflammatory cytokine biosynthesis","volume":"372","author":"Lee","year":"1994","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib121","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0092-8674(94)90277-1","article-title":"A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins","volume":"78","author":"Rouse","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.pharmr.2026.100128_bib122","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/352371","article-title":"Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses","volume":"2014","author":"Yang","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100128_bib123","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1074\/jbc.270.13.7420","article-title":"Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine","volume":"270","author":"Raingeaud","year":"1995","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100128_bib124","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1101\/gad.1107303","article-title":"Mechanism of p38 MAP kinase activation in vivo","volume":"17","author":"Brancho","year":"2003","journal-title":"Genes Dev"},{"issue":"5558","key":"10.1016\/j.pharmr.2026.100128_bib125","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.1067289","article-title":"MAPKK-independent activation of p38\u03b1 mediated by TAB1-dependent autophosphorylation of p38\u03b1","volume":"295","author":"Ge","year":"2002","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100128_bib126","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1093\/emboj\/cdg552","article-title":"Feedback control of the protein kinase TAK1 by SAPK2a\/p38\u03b1","volume":"22","author":"Cheung","year":"2003","journal-title":"EMBO J"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib127","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1074\/jbc.275.8.5966","article-title":"ZAP-70 is essential for the T cell antigen receptor-induced plasma membrane targeting of SOS and Vav in T cells","volume":"275","author":"Salojin","year":"2000","journal-title":"J Biol Chem"},{"issue":"28","key":"10.1016\/j.pharmr.2026.100128_bib128","doi-asserted-by":"crossref","first-page":"19511","DOI":"10.1074\/jbc.M801074200","article-title":"Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs","volume":"283","author":"Sheridan","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100128_bib129","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.22092.1","article-title":"An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signaling","volume":"9","author":"Han","year":"2020","journal-title":"F1000Res"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100128_bib130","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.biocel.2007.06.013","article-title":"The mitogen-activated protein kinase p38 regulates activator protein 1 by direct phosphorylation of c-Jun","volume":"39","author":"Humar","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib131","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3390\/molecules22081287","article-title":"Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer\u2019s disease","volume":"22","author":"Lee","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.pharmr.2026.100128_bib132","doi-asserted-by":"crossref","DOI":"10.1038\/srep45306","article-title":"Neuronal p38\u03b1 mediates synaptic and cognitive dysfunction in an Alzheimer\u2019s mouse model by controlling \u03b2-amyloid production","volume":"7","author":"Coli\u00e9","year":"2017","journal-title":"Sci Rep"},{"issue":"6314","key":"10.1016\/j.pharmr.2026.100128_bib133","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.aah6205","article-title":"Site-specific phosphorylation of tau inhibits amyloid-\u03b2 toxicity in Alzheimer\u2019s mice","volume":"354","author":"Ittner","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.pharmr.2026.100128_bib134","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neuroscience.2022.01.005","article-title":"High level forebrain expression of active tau kinase p38gamma exacerbates cognitive dysfunction in aged APP-transgenic Alzheimer\u2019s mice","volume":"484","author":"Asih","year":"2022","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13195-016-0221-y","article-title":"Selective suppression of the \u03b1 isoform of p38 MAPK rescues late-stage tau pathology","volume":"8","author":"Maphis","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"695","key":"10.1016\/j.pharmr.2026.100128_bib136","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq6089","article-title":"Inhibition of p38\u03b1 MAPK restores neuronal p38gamma MAPK and ameliorates synaptic degeneration in a mouse model of DLB\/PD","volume":"15","author":"Iba","year":"2023","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib137","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13195-021-00843-2","article-title":"A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 \u03b1 kinase inhibitor neflamapimod in mild Alzheimer\u2019s disease","volume":"13","author":"Prins","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib138","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1038\/s41467-022-32944-3","article-title":"Preclinical and randomized clinical evaluation of the p38\u03b1 kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat Commun"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100128_bib139","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121144","article-title":"The TAB1-p38\u03b1 complex aggravates myocardial injury and can be targeted by small molecules","volume":"3","author":"De Nicola","year":"2018","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100128_bib140","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1073\/pnas.0701679104","article-title":"Molecular basis of MAPK-activated protein kinase 2:p38 assembly","volume":"104","author":"White","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6663","key":"10.1016\/j.pharmr.2026.100128_bib141","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.add7859","article-title":"Architecture of the MKK6-p38\u03b1 complex defines the basis of MAPK specificity and activation","volume":"381","author":"Juyoux","year":"2023","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100128_bib142","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0969-2126(99)80173-7","article-title":"The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation","volume":"7","author":"Bellon","year":"1999","journal-title":"Structure"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100128_bib143","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1172\/JCI64896","article-title":"IL-13-induced airway mucus production is attenuated by MAPK13 inhibition","volume":"122","author":"Alevy","year":"2012","journal-title":"J Clin Invest"},{"issue":"5250","key":"10.1016\/j.pharmr.2026.100128_bib144","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100128_bib145","doi-asserted-by":"crossref","first-page":"16201","DOI":"10.1074\/jbc.M100873200","article-title":"Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk","volume":"276","author":"Saito","year":"2001","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100128_bib146","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2011-12-397919","article-title":"Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice","volume":"119","author":"Kil","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib147","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-020-02204-z","article-title":"Inhibition of bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease","volume":"140","author":"Torke","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib148","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3390\/cells14060414","article-title":"Pharmacological inhibition of microglial proliferation supports blood-brain barrier integrity in experimental autoimmune encephalomyelitis","volume":"14","author":"Borjini","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib149","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54430-8","article-title":"BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis","volume":"15","author":"Gruber","year":"2024","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100128_bib150","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.pharmr.2026.100128_bib151","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1182\/blood.2020009688","article-title":"Phase 2 study of ibrutinib in classic and variant hairy cell leukemia","volume":"137","author":"Rogers","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib152","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1007\/s00277-024-05921-7","article-title":"Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis","volume":"103","author":"Nunes","year":"2024","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib153","first-page":"2277","article-title":"Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database","volume":"109","author":"Brown","year":"2024","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100128_bib154","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2026.100128_bib155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","article-title":"The development of bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review","volume":"151","author":"Liang","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib156","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ncl.2023.07.006","article-title":"Bruton's tyrosine kinase inhibitors for multiple sclerosis treatment: a new frontier","volume":"42","author":"Greenberg","year":"2024","journal-title":"Neurol Clin"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib157","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/cts.12713","article-title":"Safety, tolerability, pharmacokinetics, target occupancy, and concentration-QT analysis of the Novel BTK Inhibitor evobrutinib in healthy volunteers","volume":"13","author":"Becker","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib158","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/cpt.1056","article-title":"Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible bruton's tyrosine kinase inhibitor","volume":"103","author":"Herman","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib159","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1021\/acs.jmedchem.1c00926","article-title":"Discovery and preclinical characterization of BIIB091, a reversible, selective BTK inhibitor for the treatment of multiple sclerosis","volume":"65","author":"Hopkins","year":"2022","journal-title":"J Med Chem"},{"issue":"44","key":"10.1016\/j.pharmr.2026.100128_bib160","doi-asserted-by":"crossref","first-page":"41435","DOI":"10.1074\/jbc.M104828200","article-title":"Crystal structure of bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia","volume":"276","author":"Mao","year":"2001","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib161","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0969-2126(99)80057-4","article-title":"Structure of the PH domain from bruton's tyrosine kinase in complex with inositol 1,3,4,5-tetrakisphosphate","volume":"7","author":"Baraldi","year":"1999","journal-title":"Structure"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100128_bib162","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1021\/bi972409f","article-title":"Solution structure of the SH3 domain from bruton's tyrosine kinase","volume":"37","author":"Hansson","year":"1998","journal-title":"Biochemistry"},{"issue":"8016","key":"10.1016\/j.pharmr.2026.100128_bib163","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with \u0391Fold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib164","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1073\/pnas.051626198","article-title":"BLNK mediates Syk-dependent Btk activation","volume":"98","author":"Baba","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100128_bib165","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1074\/jbc.RA119.011946","article-title":"Noncatalytic Bruton's tyrosine kinase activates PLC\u03b32 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells","volume":"295","author":"Wist","year":"2020","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib166","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling","volume":"91","author":"Bender","year":"2017","journal-title":"Mol Pharmacol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib167","doi-asserted-by":"crossref","first-page":"8122","DOI":"10.1021\/acs.jmedchem.4c00220","article-title":"Discovery and preclinical characterization of BIIB129, a covalent, selective, and brain-penetrant BTK inhibitor for the treatment of multiple sclerosis","volume":"67","author":"Himmelbauer","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2026.100128_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129108","article-title":"Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK\/PD mouse model","volume":"80","author":"Vandeveer","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib169","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/s41467-020-16128-5","article-title":"Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms","volume":"11","author":"Duarte","year":"2020","journal-title":"Nat Commun"},{"issue":"5885","key":"10.1016\/j.pharmr.2026.100128_bib170","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/299744a0","article-title":"Transforming gene of a human leukaemia cell is unrelated to the expressed tumour virus related gene of the cell","volume":"299","author":"Ozanne","year":"1982","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100128_bib171","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.7150\/ijms.73740","article-title":"Roles for c-Abl in postoperative neurodegeneration","volume":"19","author":"Feng","year":"2022","journal-title":"Int J Med Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib172","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib173","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.cr.7290261","article-title":"Role of c-Abl in the DNA damage stress response","volume":"15","author":"Shaul","year":"2005","journal-title":"Cell Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib174","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092309","article-title":"EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-\u03b2 oligomers","volume":"9","author":"Vargas","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib175","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3233\/JAD-2010-1271","article-title":"Tau phosphorylated at tyrosine 394 is found in Alzheimer\u2019s disease tangles and can be a product of the Abl-related kinase","volume":"19","author":"Tremblay","year":"2010","journal-title":"Arg. J Alzheimers Dis"},{"issue":"28","key":"10.1016\/j.pharmr.2026.100128_bib176","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1523\/JNEUROSCI.1487-05.2005","article-title":"Tyrosine 394 is phosphorylated in Alzheimer\u2019s paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase","volume":"25","author":"Derkinderen","year":"2005","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-2009-1116","article-title":"The microtubule-associated protein tau is also phosphorylated on tyrosine","volume":"18","author":"Lebouvier","year":"2009","journal-title":"J Alzheimers Dis"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100128_bib178","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1074\/jbc.RA119.012517","article-title":"Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of Tau","volume":"295","author":"Ait-Bouziad","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100128_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2021.102031","article-title":"Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer\u2019s disease","volume":"202","author":"La Barbera","year":"2021","journal-title":"Prog Neurobiol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib180","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/JPD-171191","article-title":"c-Abl and Parkinson\u2019s disease: mechanisms and Therapeutic Potential","volume":"7","author":"Brahmachari","year":"2017","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib181","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1523\/JNEUROSCI.1833-10.2011","article-title":"Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson\u2019s disease","volume":"31","author":"Imam","year":"2011","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib182","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201419","article-title":"Structure-based design and characterization of Parkin-activating mutations","volume":"6","author":"Stevens","year":"2023","journal-title":"Life Sci Alliance"},{"issue":"569","key":"10.1016\/j.pharmr.2026.100128_bib183","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax0091","article-title":"Amyloid-like oligomerization of AIMP2 contributes to \u03b1-synuclein interaction and Lewy-like inclusion","volume":"12","author":"Ham","year":"2020","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib184","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-020-00364-w","article-title":"\u03b1-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment","volume":"15","author":"Karim","year":"2020","journal-title":"Mol Neurodegener"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100128_bib185","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson\u2019s disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib186","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12031-011-9588-1","article-title":"c-Abl in neurodegenerative disease","volume":"45","author":"Schlatterer","year":"2011","journal-title":"J Mol Neurosci"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib187","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/hmg\/ddt674","article-title":"c-Abl phosphorylates \u03b1-synuclein and regulates its degradation: implication for \u03b1-synuclein clearance and contribution to the pathogenesis of Parkinson\u2019s disease","volume":"23","author":"Mahul-Mellier","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib188","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial","volume":"77","author":"Pagan","year":"2020","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib189","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/WNF.0000000000000597","article-title":"Abelson Tyrosine kinase inhibitors in Parkinson\u2019s disease and Lewy body dementia: a systematic review, meta-analysis, and meta-regression","volume":"47","author":"Gosch Berton","year":"2024","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib190","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3233\/JAD-151087","article-title":"Reduction of blood amyloid-\u03b2 oligomers in Alzheimer\u2019s disease transgenic mice by c-Abl kinase inhibition","volume":"54","author":"Estrada","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100128_bib191","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","article-title":"The c-Abl inhibitor, radotinib HCl, is neuroprotective in a preclinical Parkinson\u2019s disease mouse model","volume":"27","author":"Lee","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib192","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065129","article-title":"Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson\u2019s disease model","volume":"8","author":"Imam","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2026.100128_bib193","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.redox.2017.06.003","article-title":"Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe\/PS1dE9 through multiple signaling pathways","volume":"13","author":"Ettcheto","year":"2017","journal-title":"Redox Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib194","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.molcel.2006.01.035","article-title":"Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase","volume":"21","author":"Nagar","year":"2006","journal-title":"Mol Cell"},{"issue":"47","key":"10.1016\/j.pharmr.2026.100128_bib195","doi-asserted-by":"crossref","first-page":"E4437","DOI":"10.1073\/pnas.1314712110","article-title":"NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors","volume":"110","author":"Skora","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib196","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1074\/jbc.274.8.4995","article-title":"Engineering the substrate specificity of the Abl tyrosine kinase","volume":"274","author":"Till","year":"1999","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib197","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0040144","article-title":"A Src-like inactive conformation in the abl tyrosine kinase domain","volume":"4","author":"Levinson","year":"2006","journal-title":"PLoS Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib198","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib199","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2006-03-013250","article-title":"INNO-406, a novel BCR-ABL\/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity","volume":"109","author":"Yokota","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40478-021-01181-y","article-title":"Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis","volume":"9","author":"Peikert","year":"2021","journal-title":"Acta Neuropathol Commun"},{"issue":"S1","key":"10.1016\/j.pharmr.2026.100128_bib201","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.5045\/br.2023.2023017","article-title":"Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase","volume":"58","author":"Choi","year":"2023","journal-title":"Blood Res"},{"issue":"7280","key":"10.1016\/j.pharmr.2026.100128_bib202","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib203","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1002\/j.1460-2075.1992.tb05360.x","article-title":"A family of human cdc2-related protein kinases","volume":"11","author":"Meyerson","year":"1992","journal-title":"EMBO J"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100128_bib204","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1523\/JNEUROSCI.21-17-06758.2001","article-title":"p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment","volume":"21","author":"Ko","year":"2001","journal-title":"J Neurosci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib205","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1101\/gad.10.7.816","article-title":"The cdk5\/p35 kinase is essential for neurite outgrowth during neuronal differentiation","volume":"10","author":"Nikolic","year":"1996","journal-title":"Genes Dev"},{"issue":"6496","key":"10.1016\/j.pharmr.2026.100128_bib206","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/371419a0","article-title":"p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5","volume":"371","author":"Tsai","year":"1994","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib207","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1523\/JNEUROSCI.22-07-02590.2002","article-title":"Cdk5\/p35 regulates neurotransmitter release through phosphorylation and downregulation of P\/Q-type voltage-dependent calcium channel activity","volume":"22","author":"Tomizawa","year":"2002","journal-title":"J Neurosci"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100128_bib208","first-page":"3421","article-title":"Phosphorylation of p35 and p39 by Cdk5 determines the subcellular location of the holokinase in a phosphorylation-site-specific manner","volume":"125","author":"Asada","year":"2012","journal-title":"J Cell Sci"},{"issue":"6784","key":"10.1016\/j.pharmr.2026.100128_bib209","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/35012636","article-title":"Neurotoxicity induces cleavage of p35 to p25 by calpain","volume":"405","author":"Lee","year":"2000","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib210","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0896-6273(03)00627-5","article-title":"Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles","volume":"40","author":"Cruz","year":"2003","journal-title":"Neuron"},{"issue":"6762","key":"10.1016\/j.pharmr.2026.100128_bib211","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/45159","article-title":"Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration","volume":"402","author":"Patrick","year":"1999","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib212","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1074\/jbc.M109645200","article-title":"Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29","volume":"277","author":"Patzke","year":"2002","journal-title":"J Biol Chem"},{"issue":"38","key":"10.1016\/j.pharmr.2026.100128_bib213","doi-asserted-by":"crossref","first-page":"13148","DOI":"10.1523\/JNEUROSCI.1379-15.2015","article-title":"Phosphorylation by PKA and Cdk5 mediates the early effects of synapsin III in neuronal morphological maturation","volume":"35","author":"Piccini","year":"2015","journal-title":"J Neurosci"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100128_bib214","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1074\/jbc.273.9.4957","article-title":"Regulation of Munc-18\/syntaxin 1A interaction by cyclin-dependent kinase 5 in nerve endings","volume":"273","author":"Shuang","year":"1998","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib215","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1083\/jcb.200308110","article-title":"Cophosphorylation of amphiphysin I and dynamin I by Cdk5 regulates clathrin-mediated endocytosis of synaptic vesicles","volume":"163","author":"Tomizawa","year":"2003","journal-title":"J Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib216","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0896-6273(01)00268-9","article-title":"Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions","volume":"30","author":"Nguyen","year":"2001","journal-title":"Neuron"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100128_bib217","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1093\/hmg\/ddv188","article-title":"CDK5 phosphorylates DRP1 and drives mitochondrial defects in NMDA-induced neuronal death","volume":"24","author":"Jahani-Asl","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmr.2026.100128_bib218","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fnmol.2014.00065","article-title":"Physiological and pathological phosphorylation of tau by Cdk5","volume":"7","author":"Kimura","year":"2014","journal-title":"Front Mol Neurosci"},{"issue":"1\u20133","key":"10.1016\/j.pharmr.2026.100128_bib219","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0014-5793(03)00714-2","article-title":"Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35\/Cdk5 and p25\/Cdk5","volume":"547","author":"Liu","year":"2003","journal-title":"FEBS Lett"},{"issue":"41","key":"10.1016\/j.pharmr.2026.100128_bib220","doi-asserted-by":"crossref","first-page":"10536","DOI":"10.1523\/JNEUROSCI.3133-06.2006","article-title":"p25\/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid \u03b2 in vivo","volume":"26","author":"Cruz","year":"2006","journal-title":"J Neurosci"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib221","doi-asserted-by":"crossref","first-page":"7224","DOI":"10.1074\/jbc.M111.333914","article-title":"Cdk5 protein inhibition and A\u03b242 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease","volume":"287","author":"Sadleir","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100128_bib222","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.951202","article-title":"The role of Cdk5 in neurological disorders","volume":"16","author":"Ao","year":"2022","journal-title":"Front Cell Neurosci"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100128_bib223","doi-asserted-by":"crossref","first-page":"13650","DOI":"10.1073\/pnas.2232515100","article-title":"Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson\u2019s disease","volume":"100","author":"Smith","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib224","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41531-022-00311-0","article-title":"Cdk5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson\u2019s disease","volume":"8","author":"Yan","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib225","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1021\/jm960666x","article-title":"Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds","volume":"40","author":"Havl\u00edcek","year":"1997","journal-title":"J Med Chem"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2026.100128_bib226","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","article-title":"Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5","volume":"243","author":"Meijer","year":"1997","journal-title":"Eur J Biochem"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100128_bib227","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/1078-0432.CCR-04-2264","article-title":"In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202","volume":"11","author":"Raynaud","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib228","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1097-2765(01)00343-4","article-title":"Structure and regulation of the CDK5-p25(nck5a) complex","volume":"8","author":"Tarricone","year":"2001","journal-title":"Mol Cell"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100128_bib229","doi-asserted-by":"crossref","first-page":"9600","DOI":"10.1074\/jbc.274.14.9600","article-title":"Identification of substrate binding site of cyclin-dependent kinase 5","volume":"274","author":"Sharma","year":"1999","journal-title":"J Biol Chem"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100128_bib230","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1073\/pnas.90.14.6844","article-title":"cdc2-like kinase from rat spinal cord specifically phosphorylates KSPXK motifs in neurofilament proteins: isolation and characterization","volume":"90","author":"Shetty","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib231","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090363","article-title":"Searching for novel Cdk5 substrates in brain by comparative phosphoproteomics of wild type and Cdk5\u2212\/\u2212 mice","volume":"9","author":"Contreras-Vallejos","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib232","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1021\/jm049323m","article-title":"Mechanism of CDK5\/p25 binding by CDK inhibitors","volume":"48","author":"Mapelli","year":"2005","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib233","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1021\/acs.jmedchem.1c02069","article-title":"Discovery and optimization of highly selective inhibitors of CDK5","volume":"65","author":"Daniels","year":"2022","journal-title":"J Med Chem"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2026.100128_bib234","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0304-3940(92)90839-Y","article-title":"Phosphorylation sites on tau by Tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments","volume":"148","author":"Ishiguro","year":"1992","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmr.2026.100128_bib235","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.10557.1","article-title":"Recent advances in understanding the cellular roles of GSK-3","volume":"6","author":"Cormier","year":"2017","journal-title":"F1000Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib236","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.cell.2007.05.052","article-title":"Systematic discovery of in vivo phosphorylation networks","volume":"129","author":"Linding","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.pharmr.2026.100128_bib237","article-title":"What Are the bona fide GSK3 Substrates?","volume":"2011","author":"Sutherland","year":"2011","journal-title":"Int J Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib238","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/j.1460-2075.1990.tb07419.x","article-title":"Molecular cloning and expression of glycogen synthase kinase-3\/factor A","volume":"9","author":"Woodgett","year":"1990","journal-title":"EMBO J"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib239","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1242\/jcs.138057","article-title":"GSK-3\u2014at the crossroads of cell death and survival","volume":"127","author":"Maurer","year":"2014","journal-title":"J Cell Sci"},{"key":"10.1016\/j.pharmr.2026.100128_bib240","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.neuroscience.2010.12.017","article-title":"Effect of glycogen synthase kinase 3 \u03b2-mediated presenilin 1 phosphorylation on amyloid \u03b2 production is negatively regulated by insulin receptor cleavage","volume":"177","author":"Maesako","year":"2011","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib241","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0168-0102(98)00061-3","article-title":"Activation of Tau protein kinase I\/glycogen synthase kinase-3\u03b2 by amyloid \u03b2 peptide (25\u201335) enhances phosphorylation of tau in hippocampal neurons","volume":"31","author":"Takashima","year":"1998","journal-title":"Neurosci Res"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2026.100128_bib242","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0014-5793(97)00240-8","article-title":"Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue","volume":"406","author":"Cross","year":"1997","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib243","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neulet.2006.09.026","article-title":"Age-related changes in glycogen synthase kinase 3\u03b2 (GSK3\u03b2) immunoreactivity in the central nervous system of rats","volume":"409","author":"Lee","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmr.2026.100128_bib244","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1209703","article-title":"The role of glycogen synthase kinase 3 \u03b2 in neurodegenerative diseases","volume":"16","author":"Yu","year":"2023","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118664","article-title":"Glycogen synthase kinase-3 signaling in Alzheimer\u2019s disease","volume":"1867","author":"Lauretti","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib246","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer\u2019s disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J Neurochem"},{"issue":"6938","key":"10.1016\/j.pharmr.2026.100128_bib247","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nature01640","article-title":"GSK-3\u03b1 regulates production of Alzheimer\u2019s disease amyloid-\u03b2 peptides","volume":"423","author":"Phiel","year":"2003","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib248","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00001756-200504250-00016","article-title":"Inhibition of glycogen synthase kinase-3 protects cells from intrinsic but not extrinsic oxidative stress","volume":"16","author":"King","year":"2005","journal-title":"NeuroReport"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib249","article-title":"Glycogen synthase Kinase-3 (GSK3) inhibition by lithium induces O-GlcNAcylation perturbations","volume":"21","author":"Wang","year":"2007","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib250","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/cdd.2014.179","article-title":"GSK-3\u03b2 dysregulation contributes to parkinson\u2019s-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and \u03b1-synuclein","volume":"22","author":"Credle","year":"2015","journal-title":"Cell Death Differ"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100128_bib251","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1096\/fj.08-120410","article-title":"\u0391-synuclein contributes to GSK-3\u03b2-catalyzed Tau phosphorylation in Parkinson\u2019s disease models","volume":"23","author":"Duka","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmr.2026.100128_bib252","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fnmol.2020.00081","article-title":"GSK-3\u03b2 contributes to parkinsonian dopaminergic neuron death: evidence from conditional knockout mice and tideglusib","volume":"13","author":"Li","year":"2020","journal-title":"Front Mol Neurosci"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib253","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186764","article-title":"Production of proinflammatory mediators in activated microglia is synergistically regulated by Notch-1, glycogen synthase kinase (GSK-3\u03b2) and NF-\u03baB\/p65 signalling","volume":"12","author":"Cao","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib254","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/01.wad.0000155068.23937.9b","article-title":"Does lithium therapy protect against the onset of dementia?","volume":"19","author":"Dunn","year":"2005","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib255","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib256","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.bp.110.080044","article-title":"Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial","volume":"198","author":"Forlenza","year":"2011","journal-title":"Br J Psychiatry"},{"issue":"s1","key":"10.1016\/j.pharmr.2026.100128_bib257","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.3233\/JAD-179934","article-title":"The conundrum of GSK3 inhibitors: is it the dawn of a new beginning?","volume":"64","author":"Bhat","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib258","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer\u2019s disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib259","doi-asserted-by":"crossref","first-page":"688","DOI":"10.34172\/apb.2023.071","article-title":"Role of GSK-3\u03b2 inhibitors: new promises and opportunities for Alzheimer\u2019s disease","volume":"13","author":"Shri","year":"2023","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.pharmr.2026.100128_bib260","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.977411","article-title":"Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer\u2019s disease","volume":"14","author":"Mumtaz","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib261","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/35096075","article-title":"The renaissance of GSK3","volume":"2","author":"Cohen","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib262","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/emboj\/cdg068","article-title":"Structural basis for recruitment of glycogen synthase kinase 3\u03b2 to the axin-APC scaffold complex","volume":"22","author":"Dajani","year":"2003","journal-title":"EMBO J"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100128_bib263","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0969-2126(01)00679-7","article-title":"The structure of phosphorylated GSK-3\u03b2 complexed with a peptide, FRATtide, that inhibits \u03b2-catenin phosphorylation","volume":"9","author":"Bax","year":"2001","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib264","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75020-w","article-title":"Structural modeling of GSK3\u03b2 implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs","volume":"10","author":"Balasubramaniam","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib265","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1021\/acs.jmedchem.0c01568","article-title":"Structure-based design of potent selective nanomolar type-II inhibitors of glycogen synthase kinase-3\u03b2","volume":"64","author":"Davies","year":"2021","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib266","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/0092-8674(94)90380-8","article-title":"JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain","volume":"76","author":"D\u00e9rijard","year":"1994","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib267","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0092-8674(00)00116-1","article-title":"Signal transduction by the JNK group of MAP kinases","volume":"103","author":"Davis","year":"2000","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib268","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/bj20020553","article-title":"A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab (SH3BP5), associates with mitochondria","volume":"367","author":"Wiltshire","year":"2002","journal-title":"Biochem J"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100128_bib269","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.1074\/jbc.M111.223602","article-title":"Mitochondrial c-Jun N-terminal kinase (JNK) signaling initiates physiological changes resulting in amplification of reactive oxygen species generation","volume":"286","author":"Chambers","year":"2011","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib270","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.522","article-title":"JNK interaction with Sab mediates ER stress induced inhibition of mitochondrial respiration and cell death","volume":"5","author":"Win","year":"2014","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib271","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1471-4159.2004.02479.x","article-title":"Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK)","volume":"90","author":"Yoshida","year":"2004","journal-title":"J Neurochem"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib272","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046885","article-title":"The JNK- and AKT\/GSK3\u03b2- signaling pathways converge to regulate Puma induction and neuronal apoptosis induced by trophic factor deprivation","volume":"7","author":"Ambacher","year":"2012","journal-title":"PLoS One"},{"issue":"47","key":"10.1016\/j.pharmr.2026.100128_bib273","doi-asserted-by":"crossref","first-page":"16969","DOI":"10.1523\/JNEUROSCI.4491-11.2011","article-title":"The loss of c-Jun N-terminal protein kinase activity prevents the amyloidogenic cleavage of amyloid precursor protein and the formation of amyloid plaques in vivo","volume":"31","author":"Mazzitelli","year":"2011","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib274","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/jnc.14206","article-title":"p75 neurotrophin receptor interacts with and promotes BACE1 localization in endosomes aggravating amyloidogenesis","volume":"144","author":"Saadipour","year":"2018","journal-title":"J Neurochem"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib275","first-page":"1524","article-title":"JNK Activation in Alzheimer\u2019s disease Is Driven by amyloid \u03b2 and Is Associated with Tau Pathology","volume":"14","author":"Solas","year":"2023","journal-title":"ACS Chem Neurosci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib276","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.febslet.2006.01.053","article-title":"The regulation of Bax by c-Jun N-terminal protein kinase (JNK) is a prerequisite to the mitochondrial-induced apoptotic pathway","volume":"580","author":"Papadakis","year":"2006","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib277","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/labinvest.2009.124","article-title":"Small peptide inhibitor of JNKs protects against MPTP-induced nigral dopaminergic injury via inhibiting the JNK-signaling pathway","volume":"90","author":"Pan","year":"2010","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmr.2026.100128_bib278","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.expneurol.2015.10.010","article-title":"JNK-mediated activation of ATF2 contributes to dopaminergic neurodegeneration in the MPTP mouse model of Parkinson\u2019s disease","volume":"277","author":"Huang","year":"2016","journal-title":"Exp Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib279","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1074\/jbc.M112.421354","article-title":"Blocking c-Jun N-terminal kinase (JNK) translocation to the mitochondria prevents 6-hydroxydopamine-induced toxicity in vitro and in vivo","volume":"288","author":"Chambers","year":"2013","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib280","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI12466","article-title":"C-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis","volume":"108","author":"Han","year":"2001","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib281","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.24361","article-title":"Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe\/PS1dE9 mice","volume":"77","author":"Zhou","year":"2015","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib282","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.bmcl.2011.12.027","article-title":"Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor","volume":"22","author":"Plantevin Krenitsky","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib283","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0969-2126(98)00100-2","article-title":"Crystal structure of JNK3: a kinase implicated in neuronal apoptosis","volume":"6","author":"Xie","year":"1998","journal-title":"Structure"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib284","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(00)80351-7","article-title":"Activation mechanism of the MAP kinase ERK2 by dual phosphorylation","volume":"90","author":"Canagarajah","year":"1997","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib285","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/sj.emboj.7600212","article-title":"Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125","volume":"23","author":"Heo","year":"2004","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib286","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/35000065","article-title":"A conserved docking motif in MAP kinases common to substrates, activators and regulators","volume":"2","author":"Tanoue","year":"2000","journal-title":"Nat Cell Biol"},{"issue":"245","key":"10.1016\/j.pharmr.2026.100128_bib287","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2003004","article-title":"Specificity of linear motifs that bind to a common mitogen-activated protein kinase docking groove","volume":"5","author":"Garai","year":"2012","journal-title":"Sci Signal"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100128_bib288","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.str.2012.09.021","article-title":"Structural mechanisms of allostery and autoinhibition in JNK family kinases","volume":"20","author":"Laughlin","year":"2012","journal-title":"Structure"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib289","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1074-5521(03)00159-5","article-title":"The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity","volume":"10","author":"Scapin","year":"2003","journal-title":"Chem Biol"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100128_bib290","doi-asserted-by":"crossref","first-page":"13681","DOI":"10.1073\/pnas.251194298","article-title":"SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase","volume":"98","author":"Bennett","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100128_bib291","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1016\/j.bmcl.2005.06.083","article-title":"Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3","volume":"15","author":"Swahn","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100128_bib292","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1021\/jm0310986","article-title":"Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase","volume":"48","author":"Gaillard","year":"2005","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100128_bib293","doi-asserted-by":"crossref","first-page":"6378","DOI":"10.1016\/j.bmcl.2007.08.054","article-title":"3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors","volume":"17","author":"Jiang","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100128_bib294","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1016\/j.bmcl.2009.03.086","article-title":"Synthesis and SAR of piperazine amides as novel c-Jun N-terminal kinase (JNK) inhibitors","volume":"19","author":"Shin","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib295","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: a further update","volume":"408","author":"Bain","year":"2007","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib296","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.chembiol.2011.11.010","article-title":"Discovery of potent and selective covalent inhibitors of JNK","volume":"19","author":"Zhang","year":"2012","journal-title":"Chem Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib297","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/acs.jmedchem.6b01180","article-title":"Tri- and Tetrasubstituted Pyridinylimidazoles as covalent inhibitors of c-Jun N-terminal kinase 3","volume":"60","author":"Muth","year":"2017","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib298","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/acsmedchemlett.1c00334","article-title":"N-aromatic-substituted indazole derivatives as brain-penetrant and orally bioavailable JNK3 inhibitors","volume":"12","author":"Feng","year":"2021","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib299","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/acs.jmedchem.2c01410","article-title":"Discovery of novel indazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Parkinson\u2019s disease","volume":"66","author":"Shuai","year":"2023","journal-title":"J Med Chem"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100128_bib300","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1042\/BCJ20160557","article-title":"Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors","volume":"473","author":"Ito","year":"2016","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmr.2026.100128_bib301","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12813","article-title":"Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases","volume":"5","author":"Steger","year":"2016","journal-title":"eLife"},{"issue":"46","key":"10.1016\/j.pharmr.2026.100128_bib302","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb2454","article-title":"LRRK2 mediates tubulation and vesicle sorting from lysosomes","volume":"6","author":"Bonet-Ponce","year":"2020","journal-title":"Sci Adv"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib303","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.cell.2020.08.004","article-title":"The in situ structure of Parkinson\u2019s disease-linked LRRK2","volume":"182","author":"Watanabe","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib304","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018101237","article-title":"Rab29 activation of the Parkinson\u2019s disease-associated LRRK2 kinase","volume":"38","author":"Purlyte","year":"2019","journal-title":"EMBO J"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100128_bib305","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1073\/pnas.0500617102","article-title":"Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability","volume":"102","author":"Beilina","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2026.100128_bib306","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.40202","article-title":"A pathway for Parkinson\u2019s disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain","volume":"7","author":"Dhekne","year":"2018","journal-title":"eLife"},{"issue":"7837","key":"10.1016\/j.pharmr.2026.100128_bib307","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41586-020-2673-2","article-title":"Structure of LRRK2 in Parkinson\u2019s disease and model for microtubule interaction","volume":"588","author":"Deniston","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2026.100128_bib308","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.87098","article-title":"Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson\u2019s disease-linked LRRK2 kinase","volume":"12","author":"Dhekne","year":"2023","journal-title":"eLife"},{"issue":"43","key":"10.1016\/j.pharmr.2026.100128_bib309","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2309698120","article-title":"Membrane remodeling properties of the Parkinson\u2019s disease protein LRRK2","volume":"120","author":"Wang","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib310","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202310150","article-title":"A STING-CASM-GABARAP pathway activates LRRK2 at lysosomes","volume":"224","author":"Bentley-DeSousa","year":"2025","journal-title":"J Cell Biol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib311","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1091\/mbc.e12-08-0598","article-title":"The Rilp-like proteins Rilpl1 and Rilpl2 regulate ciliary membrane content","volume":"24","author":"Schaub","year":"2013","journal-title":"Mol Biol Cell"},{"issue":"1\u20133","key":"10.1016\/j.pharmr.2026.100128_bib312","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbamcr.2003.08.008","article-title":"Roc, a Ras\/GTPase domain in complex proteins","volume":"1643","author":"Bosgraaf","year":"2003","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib313","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1073\/pnas.0709098105","article-title":"Structure of the ROC domain from the Parkinson\u2019s disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase","volume":"105","author":"Deng","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib314","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1021\/bi061960m","article-title":"GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson\u2019s disease","volume":"46","author":"Ito","year":"2007","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib315","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cellsig.2005.08.015","article-title":"LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain","volume":"18","author":"Korr","year":"2006","journal-title":"Cell Signal"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib316","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/hmg\/ddl471","article-title":"Parkinson\u2019s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity","volume":"16","author":"West","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib317","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1523\/JNEUROSCI.4566-11.2012","article-title":"ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2","volume":"32","author":"Xiong","year":"2012","journal-title":"J Neurosci"},{"issue":"47","key":"10.1016\/j.pharmr.2026.100128_bib318","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn5417","article-title":"CalDAG-GEFI acts as a guanine nucleotide exchange factor for LRRK2 to regulate LRRK2 function and neurodegeneration","volume":"10","author":"Liu","year":"2024","journal-title":"Sci Adv"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100128_bib319","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/hmg\/ddx161","article-title":"GTP binding regulates cellular localization of Parkinson\u2019s disease-associated LRRK2","volume":"26","author":"Blanca Ram\u00edrez","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib320","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1042\/BCJ20180803","article-title":"Structure and nucleotide-induced conformational dynamics of the Chlorobium tepidum Roco protein","volume":"476","author":"Deyaert","year":"2019","journal-title":"Biochem J"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100128_bib321","doi-asserted-by":"crossref","first-page":"16906","DOI":"10.1074\/jbc.M708718200","article-title":"The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation","volume":"283","author":"Greggio","year":"2008","journal-title":"J Biol Chem"},{"issue":"164","key":"10.1016\/j.pharmr.2026.100128_bib322","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004485","article-title":"Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations","volume":"4","author":"Sheng","year":"2012","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib323","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/BJ20100483","article-title":"14-3-3 binding to LRRK2 is disrupted by multiple Parkinson\u2019s disease-associated mutations and regulates cytoplasmic localization","volume":"430","author":"Nichols","year":"2010","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmr.2026.100128_bib324","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1038\/ncomms6827","article-title":"Phosphorylation of LRRK2 by casein kinase 1\u03b1 regulates trans-Golgi clustering via differential interaction with ARHGEF7","volume":"5","author":"Chia","year":"2014","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100128_bib325","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1042\/BCJ20220161","article-title":"Impact of 100 LRRK2 variants linked to Parkinson\u2019s disease on kinase activity and microtubule binding","volume":"479","author":"Kalogeropulou","year":"2022","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmr.2026.100128_bib326","article-title":"Global Parkinson\u2019s Genetics Program (GP2). Novel Parkinson's disease genetic risk factors within and across european populations","author":"Leonard","year":"2025","journal-title":"medRxiv"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib327","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/mds.27059","article-title":"Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry","volume":"32","author":"Lee","year":"2017","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib328","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1471-4159.2010.07105.x","article-title":"Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant","volume":"116","author":"Dani\u00ebls","year":"2011","journal-title":"J Neurochem"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib329","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1073\/pnas.1323285111","article-title":"Parkinson disease-associated mutation R1441H in LRRK2 prolongs the \u201cactive state\u201d of its GTPase domain","volume":"111","author":"Liao","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib330","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/hmg\/ddi439","article-title":"The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity","volume":"15","author":"Gloeckner","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib331","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nbd.2006.04.001","article-title":"Kinase activity is required for the toxic effects of mutant LRRK2\/dardarin","volume":"23","author":"Greggio","year":"2006","journal-title":"Neurobiol Dis"},{"issue":"423","key":"10.1016\/j.pharmr.2026.100128_bib332","doi-asserted-by":"crossref","first-page":"eaai7795","DOI":"10.1126\/scitranslmed.aai7795","article-title":"Functional variants in the LRRK2 gene confer shared effects on risk for Crohn\u2019s disease and Parkinson\u2019s disease","volume":"10","author":"Hui","year":"2018","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib333","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004412","article-title":"A missense LRRK2 variant is a risk factor for excessive inflammatory responses in leprosy","volume":"10","author":"Fava","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib334","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00702-011-0653-2","article-title":"Parkinson\u2019s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures","volume":"118","author":"Hakimi","year":"2011","journal-title":"J Neural Transm"},{"issue":"511","key":"10.1016\/j.pharmr.2026.100128_bib335","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aas9292","article-title":"Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner","volume":"11","author":"Shutinoski","year":"2019","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib336","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/cdd.2012.42","article-title":"(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD","volume":"19","author":"Chen","year":"2012","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib337","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nn.3350","article-title":"Interplay of LRRK2 with chaperone-mediated autophagy","volume":"16","author":"Orenstein","year":"2013","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib338","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s40478-019-0836-x","article-title":"Alzheimer\u2019s disease tau is a prominent pathology in LRRK2 Parkinson\u2019s disease","volume":"7","author":"Henderson","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib339","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nn.2349","article-title":"Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson\u2019s disease","volume":"12","author":"Li","year":"2009","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib340","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nbd.2010.07.010","article-title":"Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice","volume":"40","author":"Melrose","year":"2010","journal-title":"Neurobiol Dis"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib341","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2005894118","article-title":"Pathogenic LRRK2 regulates ciliation probability upstream of tau tubulin kinase 2 via Rab10 and RILPL1 proteins","volume":"118","author":"Sobu","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib342","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2412029122","article-title":"Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain","volume":"122","author":"Bagnoli","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"50","key":"10.1016\/j.pharmr.2026.100128_bib343","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj1205","article-title":"Parkinson\u2019s VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B","volume":"9","author":"Pal","year":"2023","journal-title":"Sci Adv"},{"issue":"7068","key":"10.1016\/j.pharmr.2026.100128_bib344","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nature04136","article-title":"Endophilin and CtBP\/BARS are not acyl transferases in endocytosis or Golgi fission","volume":"438","author":"Gallop","year":"2005","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib345","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.neuron.2012.08.022","article-title":"LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis","volume":"75","author":"Matta","year":"2012","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib346","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.neuron.2016.09.037","article-title":"A LRRK2-dependent EndophilinA Phosphoswitch is critical for macroautophagy at presynaptic terminals","volume":"92","author":"Soukup","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.pharmr.2026.100128_bib347","article-title":"A pathogenic variant in RAB32 causes autosomal dominant Parkinson\u2019s disease and activates LRRK2 kinase","volume":"2024","author":"Gustavsson","year":"2024","journal-title":"medRxiv"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib348","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-240272","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J Parkinsons Dis"},{"issue":"540","key":"10.1016\/j.pharmr.2026.100128_bib349","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0820","article-title":"LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits","volume":"12","author":"Baptista","year":"2020","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100128_bib350","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/13543784.2023.2263357","article-title":"DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson\u2019s disease","volume":"32","author":"M\u00fcller","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmr.2026.100128_bib351","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102064","article-title":"ASO-mediated knockdown or kinase inhibition of G2019S-Lrrk2 modulates lysosomal tubule-associated antigen presentation in macrophages","volume":"34","author":"Wallings","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib352","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1073\/pnas.1817889116","article-title":"Crystal structure of the WD40 domain dimer of LRRK2","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib353","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1042\/BCJ20230477","article-title":"Role of the leucine-rich repeat protein kinase 2 C-terminal tail in domain cross-talk","volume":"481","author":"Sharma","year":"2024","journal-title":"Biochem J"},{"issue":"6677","key":"10.1016\/j.pharmr.2026.100128_bib354","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1126\/science.adi9926","article-title":"Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2","volume":"382","author":"Zhu","year":"2023","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib355","doi-asserted-by":"crossref","first-page":"8434","DOI":"10.1038\/s41467-024-52723-6","article-title":"RAB12-LRRK2 complex suppresses primary ciliogenesis and regulates centrosome homeostasis in astrocytes","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"issue":"48","key":"10.1016\/j.pharmr.2026.100128_bib356","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk6191","article-title":"Inhibition of Parkinson\u2019s disease-related LRRK2 by type I and type II kinase inhibitors: activity and structures","volume":"9","author":"Sanz Murillo","year":"2023","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib357","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41421-023-00639-8","article-title":"Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov"},{"issue":"33","key":"10.1016\/j.pharmr.2026.100128_bib358","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1038\/sj.onc.1204608","article-title":"Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway","volume":"20","author":"Unoki","year":"2001","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib359","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ncb2012","article-title":"PINK1\/Parkin-mediated mitophagy is dependent on VDAC1 and p62\/SQSTM1","volume":"12","author":"Geisler","year":"2010","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000298","article-title":"PINK1 is selectively stabilized on impaired mitochondria to activate Parkin","volume":"8","author":"Narendra","year":"2010","journal-title":"PLoS Biol"},{"issue":"33","key":"10.1016\/j.pharmr.2026.100128_bib361","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1073\/pnas.0802814105","article-title":"The kinase domain of mitochondrial PINK1 faces the cytoplasm","volume":"105","author":"Zhou","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib362","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1073\/pnas.0913485107","article-title":"Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin","volume":"107","author":"Ziviani","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib363","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/hmg\/ddq526","article-title":"PINK1 cleavage at position A103 by the mitochondrial protease PARL","volume":"20","author":"Deas","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib364","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/embor.2012.14","article-title":"Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment","volume":"13","author":"Greene","year":"2012","journal-title":"EMBO Rep"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib365","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1083\/jcb.201008084","article-title":"Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL","volume":"191","author":"Jin","year":"2010","journal-title":"J Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib366","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.celrep.2017.06.022","article-title":"The ubiquitination of PINK1 is restricted to its mature 52-kDa form","volume":"20","author":"Liu","year":"2017","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib367","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.4161\/auto.26122","article-title":"The accumulation of misfolded proteins in the mitochondrial matrix is sensed by PINK1 to induce PARK2\/Parkin-mediated mitophagy of polarized mitochondria","volume":"9","author":"Jin","year":"2013","journal-title":"Autophagy"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib368","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.463","article-title":"Superoxide drives progression of Parkin\/PINK1-dependent mitophagy following translocation of Parkin to mitochondria","volume":"8","author":"Xiao","year":"2017","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib369","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.devcel.2011.12.014","article-title":"Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin","volume":"22","author":"Lazarou","year":"2012","journal-title":"Dev Cell"},{"key":"10.1016\/j.pharmr.2026.100128_bib370","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/ncomms2016","article-title":"PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria","volume":"3","author":"Okatsu","year":"2012","journal-title":"Nat Commun"},{"issue":"51","key":"10.1016\/j.pharmr.2026.100128_bib371","doi-asserted-by":"crossref","first-page":"36372","DOI":"10.1074\/jbc.M113.509653","article-title":"A dimeric PINK1-containing complex on depolarized mitochondria stimulates Parkin recruitment","volume":"288","author":"Okatsu","year":"2013","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib372","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201744981","article-title":"PINK1 autophosphorylation is required for ubiquitin recognition","volume":"19","author":"Rasool","year":"2018","journal-title":"EMBO Rep"},{"key":"10.1016\/j.pharmr.2026.100128_bib373","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.29985","article-title":"Structure of PINK1 and mechanisms of Parkinson\u2019s disease-associated mutations","volume":"6","author":"Kumar","year":"2017","journal-title":"eLife"},{"issue":"7683","key":"10.1016\/j.pharmr.2026.100128_bib374","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature24645","article-title":"Structure of PINK1 in complex with its substrate ubiquitin","volume":"552","author":"Schubert","year":"2017","journal-title":"Nature"},{"issue":"7503","key":"10.1016\/j.pharmr.2026.100128_bib375","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nature13392","article-title":"Ubiquitin is phosphorylated by PINK1 to activate parkin","volume":"510","author":"Koyano","year":"2014","journal-title":"Nature"},{"issue":"7714","key":"10.1016\/j.pharmr.2026.100128_bib376","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-018-0224-x","article-title":"Mechanism of parkin activation by PINK1","volume":"559","author":"Gladkova","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib377","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.120080","article-title":"PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating serine 65","volume":"2","author":"Kondapalli","year":"2012","journal-title":"Open Biol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib378","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41594-018-0088-7","article-title":"Mechanism of parkin activation by phosphorylation","volume":"25","author":"Sauv\u00e9","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.pharmr.2026.100128_bib379","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14697","article-title":"Structure-guided mutagenesis reveals a hierarchical mechanism of Parkin activation","volume":"8","author":"Tang","year":"2017","journal-title":"Nat Commun"},{"issue":"46","key":"10.1016\/j.pharmr.2026.100128_bib380","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj0722","article-title":"Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1","volume":"7","author":"Antico","year":"2021","journal-title":"Sci Adv"},{"issue":"7445","key":"10.1016\/j.pharmr.2026.100128_bib381","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nature12043","article-title":"Landscape of the Parkin-dependent ubiquitylome in response to mitochondrial depolarization","volume":"496","author":"Sarraf","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib382","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/embj.201385902","article-title":"Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control","volume":"33","author":"McLelland","year":"2014","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib383","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1083\/jcb.200809125","article-title":"Parkin is recruited selectively to impaired mitochondria and promotes their autophagy","volume":"183","author":"Narendra","year":"2008","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmr.2026.100128_bib384","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2020.03.003","article-title":"Comprehensive assessment of PINK1 variants in Parkinson\u2019s disease","volume":"91","author":"Krohn","year":"2020","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib385","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41531-021-00258-8","article-title":"Systematic analysis of PINK1 variants of unknown significance shows intact mitophagy function for most variants","volume":"7","author":"Ma","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib386","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1080\/15548627.2021.1896924","article-title":"Mt-Keima detects PINK1-PRKN mitophagy in vivo with greater sensitivity than mito-QC","volume":"17","author":"Liu","year":"2021","journal-title":"Autophagy"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100128_bib387","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1073\/pnas.1221132110","article-title":"The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo","volume":"110","author":"Vincow","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7324","key":"10.1016\/j.pharmr.2026.100128_bib388","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","article-title":"Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1","volume":"468","author":"Guzman","year":"2010","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100128_bib389","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","article-title":"Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons","volume":"25","author":"Pacelli","year":"2015","journal-title":"Curr Biol"},{"issue":"7766","key":"10.1016\/j.pharmr.2026.100128_bib390","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1405-y","article-title":"Intestinal infection triggers Parkinson\u2019s disease-like symptoms in Pink1\u2212\/\u2212 mice","volume":"571","author":"Matheoud","year":"2019","journal-title":"Nature"},{"issue":"7722","key":"10.1016\/j.pharmr.2026.100128_bib391","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41586-018-0448-9","article-title":"Parkin and PINK1 mitigate STING-induced inflammation","volume":"561","author":"Sliter","year":"2018","journal-title":"Nature"},{"issue":"7097","key":"10.1016\/j.pharmr.2026.100128_bib392","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/nature04779","article-title":"Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin","volume":"441","author":"Clark","year":"2006","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100128_bib393","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/hmg\/ddi074","article-title":"Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis","volume":"14","author":"Greene","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100128_bib394","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1073\/pnas.0737556100","article-title":"Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants","volume":"100","author":"Greene","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib395","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41531-025-00945-w","article-title":"PINK1 deficiency rewires early immune responses in a mouse model of Parkinson\u2019s disease triggered by intestinal infection","volume":"11","author":"Recinto","year":"2025","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib396","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cell.2013.07.030","article-title":"A neo-substrate that amplifies catalytic activity of parkinson\u2019s-disease-related kinase PINK1","volume":"154","author":"Hertz","year":"2013","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib397","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1021\/acs.jmedchem.6b01897","article-title":"Kinetin riboside and its ProTides activate the Parkinson\u2019s disease associated PTEN-induced putative kinase 1 (PINK1) independent of mitochondrial depolarization","volume":"60","author":"Osgerby","year":"2017","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib398","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/10409238.2018.1491525","article-title":"New insights into the structure of PINK1 and the mechanism of ubiquitin phosphorylation","volume":"53","author":"Rasool","year":"2018","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"35","key":"10.1016\/j.pharmr.2026.100128_bib399","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ady0240","article-title":"Putative PINK1\/Parkin activators lower the threshold for mitophagy by sensitizing cells to mitochondrial stress","volume":"11","author":"Rosencrans","year":"2025","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib400","doi-asserted-by":"crossref","first-page":"7739","DOI":"10.1038\/s41598-024-58285-3","article-title":"Identification and structural characterization of small molecule inhibitors of PINK1","volume":"14","author":"Rasool","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib401","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1038\/s44321-025-00323-2","article-title":"Isoginkgetin antagonizes ALS pathologies in its animal and patient iPSC models via PINK1-Parkin-dependent mitophagy","volume":"17","author":"Li","year":"2025","journal-title":"EMBO Mol Med"},{"issue":"7287","key":"10.1016\/j.pharmr.2026.100128_bib402","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib403","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.molcel.2021.11.012","article-title":"Mechanism of PINK1 activation by autophosphorylation and insights into assembly on the TOM complex","volume":"82","author":"Rasool","year":"2022","journal-title":"Mol Cell"},{"issue":"7896","key":"10.1016\/j.pharmr.2026.100128_bib404","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-021-04340-2","article-title":"Activation mechanism of PINK1","volume":"602","author":"Gan","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib405","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.210264","article-title":"Mapping of a N-terminal \u03b1-helix domain required for human PINK1 stabilization, serine228 autophosphorylation and activation in cells","volume":"12","author":"Kakade","year":"2022","journal-title":"Open Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib406","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112454","article-title":"TIM23 facilitates PINK1 activation by safeguarding against OMA1-mediated degradation in damaged mitochondria","volume":"42","author":"Akabane","year":"2023","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib407","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2313540121","article-title":"Tom20 gates PINK1 activity and mediates its tethering of the TOM and TIM23 translocases upon mitochondrial stress","volume":"121","author":"Eldeeb","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100128_bib408","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn7191","article-title":"Mechanism of human PINK1 activation at the TOM complex in a reconstituted system","volume":"10","author":"Raimi","year":"2024","journal-title":"Sci Adv"},{"issue":"6744","key":"10.1016\/j.pharmr.2026.100128_bib409","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1126\/science.adu6445","article-title":"Structure of human PINK1 at a mitochondrial TOM-VDAC array","volume":"388","author":"Callegari","year":"2025","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib410","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj7408","article-title":"Interaction of PINK1 with nucleotides and kinetin","volume":"10","author":"Gan","year":"2024","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib411","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28656-8","article-title":"Structural insights into ubiquitin phosphorylation by PINK1","volume":"8","author":"Okatsu","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib412","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00018-010-0520-6","article-title":"Mechanistic principles of RAF kinase signaling","volume":"68","author":"Udell","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100128_bib413","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tibs.2014.08.004","article-title":"Dimerization-induced allostery in protein kinase regulation","volume":"39","author":"Lavoie","year":"2014","journal-title":"Trends Biochem Sci"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100128_bib414","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1021\/ci100076j","article-title":"Molecular dynamics simulations and elastic network analysis of protein kinase B (Akt\/PKB) inactivation","volume":"50","author":"Cheng","year":"2010","journal-title":"J Chem Inf Model"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100128_bib415","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1074-5521(99)80088-X","article-title":"Paradoxical activation of Raf by a novel Raf inhibitor","volume":"6","author":"Hall-Jackson","year":"1999","journal-title":"Chem Biol"},{"issue":"5650","key":"10.1016\/j.pharmr.2026.100128_bib416","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1126\/science.1090031","article-title":"Bypassing a kinase activity with an ATP-competitive drug","volume":"302","author":"Papa","year":"2003","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib417","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0955-0674(00)00219-2","article-title":"Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals","volume":"13","author":"Patil","year":"2001","journal-title":"Curr Opin Cell Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100128_bib418","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib419","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100128_bib420","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nrd3600","article-title":"Crizotinib","volume":"10","author":"Shaw","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"7928","key":"10.1016\/j.pharmr.2026.100128_bib421","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41586-022-05213-y","article-title":"Brain-restricted mTOR inhibition with binary pharmacology","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2026.100128_bib422","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neuropharm.2016.02.014","article-title":"Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound","volume":"120","author":"Poon","year":"2017","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100128_bib423","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1073\/pnas.88.11.4771","article-title":"Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier","volume":"88","author":"Friden","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5990","key":"10.1016\/j.pharmr.2026.100128_bib424","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/312162a0","article-title":"Transferrin receptor on endothelium of brain capillaries","volume":"312","author":"Jefferies","year":"1984","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100128_bib425","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib426","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12645-021-00084-w","article-title":"Lipid polymeric nanoparticles modified with tight junction-modulating peptides promote afatinib delivery across a blood-brain barrier model","volume":"12","author":"Lo","year":"2021","journal-title":"Cancer Nanotechnol"},{"key":"10.1016\/j.pharmr.2026.100128_bib427","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejps.2017.02.032","article-title":"Nose-to-brain transport of imatinib mesylate: a pharmacokinetic evaluation","volume":"102","author":"Hada","year":"2017","journal-title":"Eur J Pharm Sci"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100128_bib428","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S ibrutinib-resistance mutation in Bruton's tyrosine kinase using PROTAC-mediated degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100128_bib429","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41467-023-44237-4","article-title":"DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance","volume":"15","author":"Schr\u00f6der","year":"2024","journal-title":"Nat Commun"},{"issue":"6682","key":"10.1016\/j.pharmr.2026.100128_bib430","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100128_bib431","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100128_bib432","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1021\/acs.jmedchem.9b01264","article-title":"Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von hippel-Lindau (VHL) E3 ubiquitin ligase","volume":"62","author":"Zhao","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2026.100128_bib433","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129449","article-title":"Development of a highly potent and selective degrader of LRRK2","volume":"94","author":"Hatcher","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"issue":"37","key":"10.1016\/j.pharmr.2026.100128_bib434","doi-asserted-by":"crossref","first-page":"16930","DOI":"10.1021\/jacs.2c05499","article-title":"Discovery of XL01126: a potent, fast, cooperative, selective, orally bioavailable, and blood-brain barrier penetrant PROTAC degrader of leucine-rich repeat kinase 2","volume":"144","author":"Liu","year":"2022","journal-title":"J Am Chem Soc"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100128_bib435","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/antib12030043","article-title":"Proteolysis-targeting chimera (PROTAC) delivery into the brain across the blood-brain barrier","volume":"12","author":"Tashima","year":"2023","journal-title":"Antibodies"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:44:39Z","timestamp":1779446679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":435,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0031699726000165"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100128","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting of kinases to treat neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100128"}}